Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Nov 28;22(44):9794-9802.
doi: 10.3748/wjg.v22.i44.9794.

Association between Helicobacter pylori status and metachronous gastric cancer after endoscopic resection

Sung Bum Kim  1 , Si Hyung Lee  1 , Seung Il Bae  1 , Yo Han Jeong  1 , Se Hoon Sohn  1 , Kyeong Ok Kim  1 , Byung Ik Jang  1 , Tae Nyeun Kim  1
Affiliations

Association between Helicobacter pylori status and metachronous gastric cancer after endoscopic resection

Sung Bum Kim et al. World J Gastroenterol. .

Abstract

Aim: To investigate the effect of Helicobacter pylori (H. pylori) status test and H. pylori eradication on the occurrence of metachronous gastric cancer (MGC) after endoscopic submucosal dissection (ESD) of early gastric cancer (EGC) and risk factors of MGC.

Methods: The authors retrospectively reviewed the medical records of 433 patients (441 lesions) who underwent ESD for EGC from January 2005 to January 2015 in Yeungnam University Hospital. Patients were categorized into two groups; the H. pylori tested group (n = 257) and the H. pylori non-tested group (n = 176) based on performance of H. pylori status test after ESD of EGC. The H. pylori tested group was further categorized into three subgroups based on H. pylori status; the H. pylori-eradicated subgroup (n = 120), the H. pylori-persistent subgroup (n = 42), and the H. pylori-negative subgroup (n = 95). Incidences of MGC and risk factors of MGC were identified.

Results: Median follow-up duration after ESD was 30.00 mo (range, 6-107 mo). Total 15 patients developed MGC during follow-up. MGC developed in 11 patients of the H. pylori tested group (7 in the H. pylori-negative subgroup, 3 in the H. pylori-eradicated subgroup, and 1 in the H. pylori-persistent subgroup) and 4 patients of the H. pylori non-tested group (P > 0.05). The risk factors of MGC were endoscopic mucosal atrophy in the H. pylori tested group and intestinal metaplasia in all patients.

Conclusion: H. pylori eradication and H. pylori status test seems to have no preventive effect on the development of MGC after ESD for EGC. The risk factors of MGC development were endoscopic mucosal atrophy in the H. pylori tested group alone and intestinal metaplasia in all patients.

Keywords: Endoscopic submucosal dissection; Helicobacter pylori; Metachronous gastric cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: We have no conflict-of-interest to disclose.

Figures

Figure 1
Figure 1
Study flowchart. EGC: Early gastric cancer; ESD: Endoscopic submucosal dissection; H. pylori: Helicobacter pylori.
See this image and copyright information in PMC

References

    1. Kim SG. Endoscopic treatment for early gastric cancer. J Gastric Cancer. 2011;11:146–154. - PMC - PubMed
    1. Wang KK, Prasad G, Tian J. Endoscopic mucosal resection and endoscopic submucosal dissection in esophageal and gastric cancers. Curr Opin Gastroenterol. 2010;26:453–458. - PMC - PubMed
    1. Isomoto H, Shikuwa S, Yamaguchi N, Fukuda E, Ikeda K, Nishiyama H, Ohnita K, Mizuta Y, Shiozawa J, Kohno S. Endoscopic submucosal dissection for early gastric cancer: a large-scale feasibility study. Gut. 2009;58:331–336. - PubMed
    1. Soetikno R, Kaltenbach T, Yeh R, Gotoda T. Endoscopic mucosal resection for early cancers of the upper gastrointestinal tract. J Clin Oncol. 2005;23:4490–4498. - PubMed
    1. Kwon YH, Heo J, Lee HS, Cho CM, Jeon SW. Failure of Helicobacter pylori eradication and age are independent risk factors for recurrent neoplasia after endoscopic resection of early gastric cancer in 283 patients. Aliment Pharmacol Ther. 2014;39:609–618. - PubMed

MeSH terms

Substances